Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1986-12-3
|
pubmed:abstractText |
Basic and clinical studies have been performed on imipenem/cilastatin sodium (MK-0787/MK-0791) in the pediatric field. Antibacterial activities of MK-0787 against 14 clinical isolates of S. aureus and 67 isolates of E. coli were determined. The MIC of MK-0787 was 0.10 microgram/ml or less against all 14 strains of S. aureus. The MIC of MK-0787 was 0.39 microgram/ml or less against all 67 strains of E. coli. The pharmacokinetics of MK-0787/MK-0791 was studied at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg. The peak serum levels of MK-0787 achieved approximately 1 hour after the administration of 10 mg/10 mg/kg and 20 mg/20 mg/kg doses were 38.6 micrograms/ml and 36.2 micrograms/ml, respectively. The serum half-lives were 0.8 hour and 0.9 hour, respectively. The total 6-hour urinary excretions were 82.1% and 66.7%, respectively. The MK-0787/MK-0791 was administered to 13 children with bacterial infections. The clinical results were excellent or good in all cases. The overall efficacy rate was 100%. As a side effect, diarrhea was observed in 1 patient. Abnormalities in laboratory findings observed were elevation of direct bilirubin in 1 patient, thrombocytosis in 2, and a prolonged prothrombin time in 1 patient. Based on the above results, it can be concluded that MK-0787/MK-0791 is a safe and effective drug to use for the treatment of pediatric infections.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cilastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclopropanes,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Imipenem,
http://linkedlifedata.com/resource/pubmed/chemical/Thienamycins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0368-2781
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1804-16
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:3534346-Bacterial Infections,
pubmed-meshheading:3534346-Child,
pubmed-meshheading:3534346-Child, Preschool,
pubmed-meshheading:3534346-Cilastatin,
pubmed-meshheading:3534346-Cyclopropanes,
pubmed-meshheading:3534346-Drug Combinations,
pubmed-meshheading:3534346-Escherichia coli,
pubmed-meshheading:3534346-Female,
pubmed-meshheading:3534346-Humans,
pubmed-meshheading:3534346-Imipenem,
pubmed-meshheading:3534346-Infant,
pubmed-meshheading:3534346-Kinetics,
pubmed-meshheading:3534346-Male,
pubmed-meshheading:3534346-Staphylococcus aureus,
pubmed-meshheading:3534346-Thienamycins
|
pubmed:year |
1986
|
pubmed:articleTitle |
[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field].
|
pubmed:publicationType |
Journal Article,
English Abstract
|